S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Henry Ford Would NEVER Have Seen This Coming (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Henry Ford Would NEVER Have Seen This Coming (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Henry Ford Would NEVER Have Seen This Coming (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
New CBOE “special perk” helps traders target income every weekend (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
Henry Ford Would NEVER Have Seen This Coming (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
Henry Ford Would NEVER Have Seen This Coming (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating

iTeos Therapeutics Stock Price, News & Analysis (NASDAQ:ITOS)

$9.84
-0.26 (-2.57%)
(As of 12/5/2023 ET)
Compare
Today's Range
$9.68
$10.13
50-Day Range
$8.58
$11.51
52-Week Range
$8.20
$23.00
Volume
402,530 shs
Average Volume
357,714 shs
Market Capitalization
$352.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.33

iTeos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
259.1% Upside
$35.33 Price Target
Short Interest
Healthy
5.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of iTeos Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$41,850 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.07) to ($5.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

99th out of 949 stocks

Biological Products, Except Diagnostic Industry

14th out of 147 stocks


ITOS stock logo

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Stock Price History

ITOS Stock News Headlines

iTeos Therapeutics (NASDAQ: ITOS)
Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
iTeos to Participate in Upcoming Investor Conferences
Why ITeos Therapeutics (ITOS) Stock Is Moving Higher
H.C. Wainwright Keeps Their Buy Rating on iTeos Therapeutics (ITOS)
iTeos Therapeutics: Trading Under Cash Value
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.33
High Stock Price Target
$44.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+259.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$96.65 million
Pretax Margin
-87.36%

Debt

Sales & Book Value

Annual Sales
$267.63 million
Cash Flow
$2.67 per share
Book Value
$18.65 per share

Miscellaneous

Free Float
32,135,000
Market Cap
$352.08 million
Optionable
Not Optionable
Beta
1.10
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report














ITOS Stock Analysis - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings
or view top-rated stocks.

What is iTeos Therapeutics' stock price target for 2024?

3 brokerages have issued 12 month target prices for iTeos Therapeutics' shares. Their ITOS share price targets range from $29.00 to $44.00. On average, they expect the company's share price to reach $35.33 in the next year. This suggests a possible upside of 259.1% from the stock's current price.
View analysts price targets for ITOS
or view top-rated stocks among Wall Street analysts.

How have ITOS shares performed in 2023?

iTeos Therapeutics' stock was trading at $19.53 at the beginning of 2023. Since then, ITOS stock has decreased by 49.6% and is now trading at $9.84.
View the best growth stocks for 2023 here
.

Are investors shorting iTeos Therapeutics?

iTeos Therapeutics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 1,590,000 shares, a decline of 9.1% from the October 31st total of 1,750,000 shares. Based on an average trading volume of 431,100 shares, the days-to-cover ratio is currently 3.7 days. Approximately 5.6% of the shares of the stock are short sold.
View iTeos Therapeutics' Short Interest
.

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our ITOS earnings forecast
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.30. iTeos Therapeutics had a negative trailing twelve-month return on equity of 9.72% and a net margin of 9.02%.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

(ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (2.26%), Deerfield Management Company L.P. Series C (2.02%), Jacobs Levy Equity Management Inc. (1.28%), Barclays PLC (0.90%), Bank of New York Mellon Corp (0.78%) and Northern Trust Corp (0.77%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends
.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ITOS) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -